Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration
Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved..
PURPOSE: To evaluate the influence of macular neovascularization (MNV) lesion type on 12-month clinical outcomes in treatment-naive eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF drugs nationwide.
DESIGN: Multicenter national nAMD database observational study.
SUBJECTS: One thousand six hundred six treatment-naive nAMD eyes (1330 patients) undergoing anti-VEGF therapy for 12 months nationwide.
METHODS: Demographics, visual acuity (VA) in logarithm of the minimum angle of resolution letters, number of injections and visits were was collected using a validated web-based tool. Neovascular lesion phenotype was classified as type 1 (T1, n = 711), type 2 (T2, n = 505), type 3 (T3, n = 315), and aneurysmal type 1 (A-T1, n = 75), according to the new proposed consensus classification.
MAIN OUTCOME MEASURES: Mean VA change at 12 months, final VA at 12 months, number of injections, time to lesion inactivation.
RESULTS: A total of 1606 treatment-naive nAMD eyes (1330 patients) received a median of 7 injections over 12 months. Mean (± standard deviation) baseline VA was significantly lower for T2 (49.4 ± 23.5 letters) compared with T1 (57.8 ± 20.8) and T3 (58.2 ± 19.4) (both P < 0.05) lesions. Mean VA change at 12 months was significantly greater for A-T1 (+9.5 letters) compared with T3 (+3.1 letters, P < 0.05). Patients with T3 lesions had fewer active visits (24.9%) than those with other lesion types (T1, 30.5%; T2, 32.6%; A-T1, 27.5%; all P < 0.05). Aflibercept was the most used drug in A-T1 lesions (70.1%) and ranibizumab in T1 (40.7%), T2 (57.7%), and T3 (47.6%) lesions.
CONCLUSIONS: This study highlights the relevance of MNV type on clinical outcomes in nAMD and reports significant differences in baseline VA, VA change, and lesion activity at 12 months. This report provides data about lesion-specific clinical features, which may guide the management of nAMD cases and potentially support personalized clinical decision making for these patients.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Ophthalmology. Retina - 8(2024), 4 vom: 25. Apr., Seite 350-359 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Age-related macular degeneration |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.oret.2023.10.022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36416798X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36416798X | ||
| 003 | DE-627 | ||
| 005 | 20240408232120.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oret.2023.10.022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM36416798X | ||
| 035 | |a (NLM)37924946 | ||
| 035 | |a (PII)S2468-6530(23)00573-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Izquierdo-Serra, Jordi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a PURPOSE: To evaluate the influence of macular neovascularization (MNV) lesion type on 12-month clinical outcomes in treatment-naive eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF drugs nationwide | ||
| 520 | |a DESIGN: Multicenter national nAMD database observational study | ||
| 520 | |a SUBJECTS: One thousand six hundred six treatment-naive nAMD eyes (1330 patients) undergoing anti-VEGF therapy for 12 months nationwide | ||
| 520 | |a METHODS: Demographics, visual acuity (VA) in logarithm of the minimum angle of resolution letters, number of injections and visits were was collected using a validated web-based tool. Neovascular lesion phenotype was classified as type 1 (T1, n = 711), type 2 (T2, n = 505), type 3 (T3, n = 315), and aneurysmal type 1 (A-T1, n = 75), according to the new proposed consensus classification | ||
| 520 | |a MAIN OUTCOME MEASURES: Mean VA change at 12 months, final VA at 12 months, number of injections, time to lesion inactivation | ||
| 520 | |a RESULTS: A total of 1606 treatment-naive nAMD eyes (1330 patients) received a median of 7 injections over 12 months. Mean (± standard deviation) baseline VA was significantly lower for T2 (49.4 ± 23.5 letters) compared with T1 (57.8 ± 20.8) and T3 (58.2 ± 19.4) (both P < 0.05) lesions. Mean VA change at 12 months was significantly greater for A-T1 (+9.5 letters) compared with T3 (+3.1 letters, P < 0.05). Patients with T3 lesions had fewer active visits (24.9%) than those with other lesion types (T1, 30.5%; T2, 32.6%; A-T1, 27.5%; all P < 0.05). Aflibercept was the most used drug in A-T1 lesions (70.1%) and ranibizumab in T1 (40.7%), T2 (57.7%), and T3 (47.6%) lesions | ||
| 520 | |a CONCLUSIONS: This study highlights the relevance of MNV type on clinical outcomes in nAMD and reports significant differences in baseline VA, VA change, and lesion activity at 12 months. This report provides data about lesion-specific clinical features, which may guide the management of nAMD cases and potentially support personalized clinical decision making for these patients | ||
| 520 | |a FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Age-related macular degeneration | |
| 650 | 4 | |a Audit | |
| 650 | 4 | |a Benchmark standard | |
| 650 | 4 | |a Outcome | |
| 650 | 4 | |a Subtype | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 700 | 1 | |a Martin-Pinardel, Ruben |e verfasserin |4 aut | |
| 700 | 1 | |a Moll-Udina, Aina |e verfasserin |4 aut | |
| 700 | 1 | |a Bernal-Morales, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Garay-Aramburu, Gonzaga |e verfasserin |4 aut | |
| 700 | 1 | |a Sanchez-Monroy, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Arruabarrena, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez-Hortelano, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Figueroa, Marta S |e verfasserin |4 aut | |
| 700 | 1 | |a Abraldes, Maximino |e verfasserin |4 aut | |
| 700 | 1 | |a Lavid de Los Mozos, Francisco Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Zapata, Miguel Angel |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Moreno, Jose Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Broc-Iturralde, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez-Guijarro, Jacobo |e verfasserin |4 aut | |
| 700 | 1 | |a Escobar-Barranco, Jose Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Gallego-Pinazo, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Parrado-Carrillo, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Dotti-Boada, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Alforja, Socorro |e verfasserin |4 aut | |
| 700 | 1 | |a Figueras-Roca, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Barthelmes, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Gillies, Mark C |e verfasserin |4 aut | |
| 700 | 1 | |a Casaroli-Marano, Ricardo P |e verfasserin |4 aut | |
| 700 | 1 | |a Zarranz-Ventura, Javier |e verfasserin |4 aut | |
| 700 | 0 | |a Writing Committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group |e verfasserin |4 aut | |
| 700 | 1 | |a Zarranz-Ventura, Javier |e investigator |4 oth | |
| 700 | 1 | |a Parrado-Carrillo, Alba |e investigator |4 oth | |
| 700 | 1 | |a Figueras-Roca, Marc |e investigator |4 oth | |
| 700 | 1 | |a Moll-Udina, Aina |e investigator |4 oth | |
| 700 | 1 | |a Izquierdo-Serra, Jordi |e investigator |4 oth | |
| 700 | 1 | |a Serrano, Alba |e investigator |4 oth | |
| 700 | 1 | |a Grau, Jose |e investigator |4 oth | |
| 700 | 1 | |a Bernal-Morales, Carolina |e investigator |4 oth | |
| 700 | 1 | |a Alforja, Socorro |e investigator |4 oth | |
| 700 | 1 | |a Casaroli-Marano, Ricardo P |e investigator |4 oth | |
| 700 | 1 | |a Sararols-Ramsay, Laura |e investigator |4 oth | |
| 700 | 1 | |a Londoño, Gabriel |e investigator |4 oth | |
| 700 | 1 | |a Olivera, Maximiliano |e investigator |4 oth | |
| 700 | 1 | |a Bañon, Karim |e investigator |4 oth | |
| 700 | 1 | |a Rethati, Cynthia |e investigator |4 oth | |
| 700 | 1 | |a Calvo, Pilar |e investigator |4 oth | |
| 700 | 1 | |a Sánchez, Jorge |e investigator |4 oth | |
| 700 | 1 | |a Puzo, Martín |e investigator |4 oth | |
| 700 | 1 | |a Ruiz-Moreno, Oscar |e investigator |4 oth | |
| 700 | 1 | |a Garay-Aramburu, Gonzaga |e investigator |4 oth | |
| 700 | 1 | |a Larrauri-Arana, Arantza |e investigator |4 oth | |
| 700 | 1 | |a Gómez-Moreno, Angela |e investigator |4 oth | |
| 700 | 1 | |a Rodríguez-Feijoo, David |e investigator |4 oth | |
| 700 | 1 | |a Diaz-de-Durana-Santa-Coloma, Enrique |e investigator |4 oth | |
| 700 | 1 | |a Aldazabal-Echeveste, Maialen |e investigator |4 oth | |
| 700 | 1 | |a Del-Barrio-Lopez-de-Ipiña, Zuriñe |e investigator |4 oth | |
| 700 | 1 | |a Herrero-Díaz, Irene |e investigator |4 oth | |
| 700 | 1 | |a García-Arumí, José |e investigator |4 oth | |
| 700 | 1 | |a Brosa, Helena |e investigator |4 oth | |
| 700 | 1 | |a Sánchez-Vela, Laura |e investigator |4 oth | |
| 700 | 1 | |a Zapata, Miguel Angel |e investigator |4 oth | |
| 700 | 1 | |a Arruabarrena, Carolina |e investigator |4 oth | |
| 700 | 1 | |a Montejano-Milner, Rafael |e investigator |4 oth | |
| 700 | 1 | |a de Aragón, Fernando |e investigator |4 oth | |
| 700 | 1 | |a Abraldes López-Veiga, Maximino José |e investigator |4 oth | |
| 700 | 1 | |a Gómez Conde, María Lidia |e investigator |4 oth | |
| 700 | 1 | |a Rodríguez-Cid, María José |e investigator |4 oth | |
| 700 | 1 | |a Fernández Rodríguez, María Isabel |e investigator |4 oth | |
| 700 | 1 | |a Almuiña Varela, Pablo |e investigator |4 oth | |
| 700 | 1 | |a Fernández-Hortelano, Ana |e investigator |4 oth | |
| 700 | 1 | |a Zarallo-Gallardo, Jesús |e investigator |4 oth | |
| 700 | 1 | |a Cobo-Soriano, Rosario |e investigator |4 oth | |
| 700 | 1 | |a Lozano-Escobar, Inmaculada |e investigator |4 oth | |
| 700 | 1 | |a Moreno-Martín, Paula |e investigator |4 oth | |
| 700 | 1 | |a Ruiz-Moreno, Jose M |e investigator |4 oth | |
| 700 | 1 | |a Vega-González, Rocío |e investigator |4 oth | |
| 700 | 1 | |a García Zamora, María |e investigator |4 oth | |
| 700 | 1 | |a Flores-Moreno, Ignacio |e investigator |4 oth | |
| 700 | 1 | |a Valldeperas, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Broc-Iturralde, Laura |e investigator |4 oth | |
| 700 | 1 | |a Mira, Ferran Vilaplana |e investigator |4 oth | |
| 700 | 1 | |a Sánchez, Sandra Gómez |e investigator |4 oth | |
| 700 | 1 | |a Figueroa, Pamela Campos |e investigator |4 oth | |
| 700 | 1 | |a Escobar-Barranco, Jose Juan |e investigator |4 oth | |
| 700 | 1 | |a Fernandez-Bonet, Manel |e investigator |4 oth | |
| 700 | 1 | |a Pina-Marín, Begoña |e investigator |4 oth | |
| 700 | 1 | |a Martínez, Eva Salinas |e investigator |4 oth | |
| 700 | 1 | |a González Guijarro, Jacobo |e investigator |4 oth | |
| 700 | 1 | |a Acebes García, Muxima |e investigator |4 oth | |
| 700 | 1 | |a Sanchís, Sonia Aparicio |e investigator |4 oth | |
| 700 | 1 | |a Fernández, Jonathan Cacelliere |e investigator |4 oth | |
| 700 | 1 | |a Belmonte Grau, Marta |e investigator |4 oth | |
| 700 | 1 | |a Ascaso Puyuelo, Francisco Javier |e investigator |4 oth | |
| 700 | 1 | |a Honrubia Grijalbo, Ana |e investigator |4 oth | |
| 700 | 1 | |a Boned Murillo, Ana |e investigator |4 oth | |
| 700 | 1 | |a Díaz Barreda, María Dolores |e investigator |4 oth | |
| 700 | 1 | |a Rivasés, Guillermo Pérez |e investigator |4 oth | |
| 700 | 1 | |a El Bakkali, Ismael Bakkali |e investigator |4 oth | |
| 700 | 1 | |a Gallego-Pinazo, Roberto |e investigator |4 oth | |
| 700 | 1 | |a Cholbi, Marta |e investigator |4 oth | |
| 700 | 1 | |a Dolz-Marco, Rosa |e investigator |4 oth | |
| 700 | 1 | |a Figueroa, Marta S |e investigator |4 oth | |
| 700 | 1 | |a Ciancas, Esther |e investigator |4 oth | |
| 700 | 1 | |a Gonzalez-López, Julio José |e investigator |4 oth | |
| 700 | 1 | |a Haskour, Cesar Azrak |e investigator |4 oth | |
| 700 | 1 | |a Sánchez, Alvaro Piñero |e investigator |4 oth | |
| 700 | 1 | |a Muñoz Sanz, Nélida |e investigator |4 oth | |
| 700 | 1 | |a Carreño, Ester |e investigator |4 oth | |
| 700 | 1 | |a Ventura, Nestor |e investigator |4 oth | |
| 700 | 1 | |a Carnota-Méndez, Pablo |e investigator |4 oth | |
| 700 | 1 | |a Méndez-Vázquez, Carlos |e investigator |4 oth | |
| 700 | 1 | |a Torres-Borrego, Carlos |e investigator |4 oth | |
| 700 | 1 | |a Velázquez-Villoria, Daniel |e investigator |4 oth | |
| 700 | 1 | |a García-Layana, Alfredo |e investigator |4 oth | |
| 700 | 1 | |a Saenz de Viteri, Manuel |e investigator |4 oth | |
| 700 | 1 | |a Alonso, Elena |e investigator |4 oth | |
| 700 | 1 | |a Castillón Torre, Luis J |e investigator |4 oth | |
| 700 | 1 | |a Muñoz, Pablo Catalán |e investigator |4 oth | |
| 700 | 1 | |a Sempere, María Eugenia Tena |e investigator |4 oth | |
| 700 | 1 | |a Álvarez Gil, María de Fátima |e investigator |4 oth | |
| 700 | 1 | |a Piñas García, Purificación |e investigator |4 oth | |
| 700 | 1 | |a Mantrana Bermejo, María Eugenia |e investigator |4 oth | |
| 700 | 1 | |a de Los Mozos, Francisco Javier Lavid |e investigator |4 oth | |
| 700 | 1 | |a Asencio Duran, Mónica |e investigator |4 oth | |
| 700 | 1 | |a Arias-Barquet, Lluis |e investigator |4 oth | |
| 700 | 1 | |a Cobos Martín, Estefanía |e investigator |4 oth | |
| 700 | 1 | |a Parra, Daniel Lorenzo |e investigator |4 oth | |
| 700 | 1 | |a Rodríguez-Núñez, Marta |e investigator |4 oth | |
| 700 | 1 | |a Gesto, Ana Campo |e investigator |4 oth | |
| 700 | 1 | |a Pareja Esteban, Jesús |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Ophthalmology. Retina |d 2017 |g 8(2024), 4 vom: 25. Apr., Seite 350-359 |w (DE-627)NLM271223650 |x 2468-6530 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g number:4 |g day:25 |g month:04 |g pages:350-359 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.oret.2023.10.022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |e 4 |b 25 |c 04 |h 350-359 | ||